Vancomycin Taper to Prevent Recurrent Clostridioides Difficile | MicrobiomeTrials← Back to trialsNCT07328971
Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-04-24Est. Completion: 2030-06-01
Enrollment target: 500 participants Locations- McGill University Health Centre, Montreal, Quebec, Canada
Other microbiome trials you might be interested in
Clostridium Difficile Colitis
It has been shown that restoration of the normal makeup of the bowel bacterial population is the most effective way to t…
Durham, United StatesEst. completion May 2027
Hospital-acquired Pneumonia
Hospital-Acquired Pneumonia (HAP) is the second most frequent hospital-acquired infection in the US and Europe and accou…
Créteil, FranceCompleted Aug 31, 2023
Completed
Cellulitis is a common condition diagnosed and managed in the ED that carries significant burden on healthcare systems g…
Calgary, CanadaCompleted Apr 5, 2026